Ultragenyx Pharmaceutical Shares Rise 5.6%

Analysts Maintain Buy Ratings Despite Price Target Cuts

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) rose 5.6% on Monday, trading as high as $22.47. The biopharmaceutical company, focused on rare and ultra-rare genetic disorders, saw its stock price increase despite a decline in trading volume compared to the average daily volume. Analysts have maintained buy ratings on the stock, though they have lowered their price targets.

Why it matters

Ultragenyx Pharmaceutical's stock performance is closely watched by investors as the company continues to develop therapies for rare genetic disorders, an area of high unmet medical need. The stock's volatility reflects the challenges and uncertainties inherent in the biotech industry, where clinical trial results and regulatory approvals can significantly impact a company's valuation.

The details

Several equity analysts have recently adjusted their price targets for Ultragenyx Pharmaceutical. HC Wainwright cut its price target from $60 to $50, while Guggenheim lowered its target from $64 to $52. Jefferies Financial Group decreased its price target from $114 to $63. Despite these target reductions, the analysts maintained their buy ratings on the stock.

  • Ultragenyx Pharmaceutical's shares rose 5.6% on Monday, March 9, 2026.

The players

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. The company is headquartered in Novato, California.

HC Wainwright

An equity research firm that covers Ultragenyx Pharmaceutical and has reduced its price target on the stock.

Guggenheim

An investment bank that has lowered its price target on Ultragenyx Pharmaceutical.

Jefferies Financial Group

A financial services firm that has decreased its price target on Ultragenyx Pharmaceutical.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Ultragenyx Pharmaceutical's stock volatility reflects the challenges and uncertainties inherent in the biotech industry, where clinical trial results and regulatory approvals can significantly impact a company's valuation. Despite price target reductions from analysts, the company maintains buy ratings, indicating their confidence in Ultragenyx's ability to develop and commercialize therapies for rare genetic disorders.